Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Two Sigma Advisers LP cut its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 95.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,800 shares of the company’s stock after selling 316,400 shares during the period. Two Sigma Advisers LP’s holdings in Cardiff Oncology were worth $64,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Orbimed Advisors LLC bought a new position in shares of Cardiff Oncology in the 4th quarter worth approximately $6,677,000. Acorn Capital Advisors LLC purchased a new stake in Cardiff Oncology in the fourth quarter worth $6,260,000. Adage Capital Partners GP L.L.C. purchased a new stake in Cardiff Oncology in the fourth quarter worth $5,609,000. Geode Capital Management LLC raised its holdings in Cardiff Oncology by 5.9% in the fourth quarter. Geode Capital Management LLC now owns 982,878 shares of the company’s stock worth $4,266,000 after purchasing an additional 54,646 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Cardiff Oncology by 73.7% during the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company’s stock valued at $2,546,000 after acquiring an additional 248,850 shares during the period. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Stock Up 7.2%

Shares of NASDAQ CRDF opened at $3.88 on Monday. The firm has a market cap of $258.12 million, a P/E ratio of -4.13 and a beta of 1.61. Cardiff Oncology, Inc. has a twelve month low of $2.01 and a twelve month high of $5.64. The company has a 50 day moving average of $2.90 and a 200 day moving average of $3.48.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.09 million. As a group, equities analysts expect that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their target price on Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, May 9th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.